AG
CMPX icon

Algert Global’s Compass Therapeutics CMPX Stock Holding History

Algert Global’s Portfolio CMPX Stock Details CMPX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$675K Buy
308,110
+271,330
+738% +$801K 0.01% 1025
2026
Q1 		$195K Buy
+36,780
New +$212K ﹤0.01% 1083
2025
Q1 		– Sell
-22,588
Closed -$32.8K – 1199
2024
Q4 		$32.8K Hold
22,588
– – ﹤0.01% 1148
2024
Q3 		$41.6K Buy
22,588
+6,008
+36% +$7.49K ﹤0.01% 1144
2024
Q2 		$16.6K Hold
16,580
– – ﹤0.01% 1478
2024
Q1 		$32.8K Buy
+16,580
New +$28.7K ﹤0.01% 1043
2023
Q4 		– Sell
-33,963
Closed -$66.9K – 1146
2023
Q3 		$66.9K Sell
33,963
-54,870
-62% -$136K ﹤0.01% 1054
2023
Q2 		$282K Buy
+88,833
New +$279K 0.01% 923

Other funds holding CMPX

TCM
Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
SCM
Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
ES
Enavate Sciences Menlo Park, California $345M AUM 134.64% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
PAI
Palo Alto Investors Palo Alto, California $724M AUM 96.91% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Algert Global's CMPX Position: Q2 2026 in Review

Algert Global increased its Compass Therapeutics (CMPX) stake by 738% in Q2 2026, buying an estimated $801K and bringing the position to 308,110 shares worth $675K. The position accounts for 0.01% of the portfolio, ranked #1025.

Algert Global first reported a position in CMPX in Q2 2023 and has held it in 8 quarters since. 216 funds tracked by Wall St. Rank hold CMPX as of Q2 2026.

  • Algert Global held 308,110 shares of Compass Therapeutics worth $675K as of Q2 2026.
  • Algert Global bought 271,330 Compass Therapeutics shares in Q2 2026, an estimated $801K.
  • Compass Therapeutics made up 0.01% of Algert Global's portfolio in Q2 2026, its #1025 holding.
  • Algert Global first reported a position in Compass Therapeutics in Q2 2023 and has held it in 8 quarters since.
  • 216 funds tracked by Wall St. Rank held Compass Therapeutics as of Q2 2026.

Based on Algert Global's 13F filing for Q2 2026, filed 13 Aug 2026.